Archive
A tighter archive for life-science signals.
Search once, then narrow by source or topic.
<a href="https://www.fiercebiotech.com/medtech/ge-healthcare-acquire-imaging-software-provider-intelerad-23b" hreflang="en">GE HealthCare to acquire imaging software provider Intelerad for $2.3B</a>
With its focus on radiology and cardiology practices, as well as assisting in clinical trials, Intelerad’s outpatient footprint will serve as a complement to GE HealthC...
Regulatory actions for Nov. 25, 2025
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Celltrion, Hen...
Regulatory actions for Nov. 24, 2025
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: BD, Ceribell, Transmural Sys...
KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors - Yahoo Finance
KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in...
Roche touts early giredestrant success | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Roche touts early giredestrant success | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Roche reports positive Phase III data of giredestrant for breast cancer - Clinical Trials Arena
Roche reports positive Phase III data of giredestrant for breast cancer Clinical Trials Arena
‘A sigh of relief’: New malaria drug succeeds in large clinical trial
As existing drugs falter because of resistance, the world gets a backup—but hard choices loom on how to use it
Roche sizes up first BTK inhibitor approval on Phase III MS victory - Clinical Trials Arena
Roche sizes up first BTK inhibitor approval on Phase III MS victory Clinical Trials Arena
Roche’s Phase III trial of Gazyva/Gazyvaro for SLE meets primary endpoint - Clinical Trials Arena
Roche’s Phase III trial of Gazyva/Gazyvaro for SLE meets primary endpoint Clinical Trials Arena